Skip to Main Content

In the last six months, Pear Therapeutics has raised $100 million, inked a bevy of new deals, and launched a sweeping study of its app to treat substance use disorders.

It has also seen a high-profile study on its digital treatment for schizophrenia fail.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED